ProCE Banner Activity

Key Decisions in HIV Care: Data on Long-Acting Injectable PrEP

Podcast Episodes
Listen as Jason Schafer, PharmD, MPH, shares the latest data to support long-acting PrEP, including efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.

Released: March 14, 2022

Expiration: March 13, 2023

Share

Faculty

Jason Schafer

Jason Schafer, PharmD, MPH

Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Jason Schafer, PharmD, MPH

Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania

Jason Schafer, MD, MPH, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Merck and ViiV.